CARE Ratings Posts Robust FY26 Performance, Declares Dividend

Standalone revenue rose 15.16% to ₹387.72 crore from ₹336.68 crore in FY25. Consolidated revenue increased 17.59% to ₹473.07 crore from ₹402.32 crore.

Reader Takeaway: Strong revenue growth and digital strategy boost financials, while litigation and regulatory shifts pose monitoring points.

What just happened

CARE Ratings Ltd announced its financial results for the fiscal year 2025-26. The company reported a standalone revenue of ₹387.72 crore, marking a 15.16% increase compared to ₹336.68 crore in the previous fiscal year. Consolidated revenue also saw significant growth, rising by 17.59% to ₹473.07 crore from ₹402.32 crore.

Profitability also improved. Standalone Profit After Tax (PAT) grew by 17.84% to ₹174.39 crore, while consolidated PAT surged by 24.07% to ₹173.70 crore. The company's standalone EBITDA margin stood at 42% and PAT margin at 33% for FY26.

The Board of Directors has recommended a final dividend of ₹14 per share, adding to the interim dividend of ₹8 per share, making a total payout of ₹22 per share for the financial year, amounting to ₹56.96 crore.

Why this matters

The strong financial performance indicates the company's ability to grow its revenue and profitability, driven by its business strategy. The significant dividend payout signals confidence in its financial health and commitment to shareholder returns. The company's focus on digital integration and AI adoption suggests efforts to enhance operational efficiency and market competitiveness.

The backstory

CARE Ratings has been focusing on implementing its digital lifecycle strategy, integrating CRM applications and adopting AI. This strategy aims to improve analytical efficiency. The company's global expansion in sovereign rating coverage and maintaining a strong market share in ESG ratings are part of its broader growth initiatives.

What changes now

The positive financial results and dividend declaration are likely to be viewed favorably by investors. The company's strategic initiatives in digital transformation and market expansion are expected to continue shaping its performance. However, ongoing legal and regulatory challenges will need to be closely managed.

Risks to watch

The company faces legal challenges, including ongoing litigation with 63 Moons Technologies Ltd, where an appeal has been filed against a Madras High Court order. Regulatory risks include potential shifts in the RBI's Internal Rating Based (IRB) approach for banks, which could affect demand for rating services. Macroeconomic factors like geopolitical instability and trade actions are also key watch points.

Peer comparison

CARE Ratings operates in a competitive environment alongside other credit rating agencies. While the filing does not provide direct peer comparison numbers, the company's reported growth rates and margin analysis can be benchmarked against industry averages and key competitors in the Indian market.

Context metrics (time-bound)

• Standalone Revenue (FY26): ₹387.72 crore (15.16% growth YoY)
• Consolidated Revenue (FY26): ₹473.07 crore (17.59% growth YoY)
• Standalone PAT (FY26): ₹174.39 crore (17.84% growth YoY)
• Consolidated PAT (FY26): ₹173.70 crore (24.07% growth YoY)
• Total Dividend recommended: ₹22 per share

What to track next

Investors will be keen to monitor the outcome of the litigation with 63 Moons Technologies Ltd and any further developments regarding RBI's IRB approach. The company's continued execution of its digital strategy and expansion in ESG ratings will also be critical factors to watch.